Intravenous use of illicit buprenorphine/naloxone to reverse an acute heroin overdose

Journal of Opioid Management

Volumn 8, Issue 1, 2012, Pages 63-66

  Yokell, Michael A ^a,b,c   Zaller, Nickolas D ^a,b,d   Green, Traci C ^b,d,e   McKenzie, Michelle ^a,b   Rich, Josiah D ^a,b,d  

^a MIRIAM HOSPITAL   (United States)

^b Lifespan   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BROWN UNIVERSITY   (United States)

^e RHODE ISLAND HOSPITAL   (United States)

Author keywords

Buprenorphine naloxone; Injection drug users; Lay responder; Naloxone; Opiate overdose; Opioid overdose; Overdose; Suboxone

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; ILLICIT DRUG; NALOXONE; OXYCODONE;

ADULT; ARTICLE; CASE REPORT; CHEMICAL COMPOSITION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG OVERDOSE; FEMALE; HEALTH PROGRAM; HEROIN OVERDOSE; HIGH RISK PATIENT; HUMAN; INTRAVENOUS DRUG ABUSE; MALE; MORTALITY; OPIATE ADDICTION; PATIENT EDUCATION; PRESCRIPTION; TABLET;

ADULT; BUPRENORPHINE; HEROIN; HUMANS; INJECTIONS, INTRAVENOUS; MALE; NALOXONE; NARCOTIC ANTAGONISTS; OVERDOSE; STREET DRUGS; TREATMENT OUTCOME;

EID: 84859081602     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2012.0098     Document Type: Article

References (25)

1. Fingerhut L: Increases in Poisoning and Methadone-Related Deaths: United States, 1999-2005- Atlanta, GA: Centers for Disease Control and Prevention, 2006. Available at http://www.cdc.gov/nchs/data/hestat/poisoning/poisoning.htm. Accessed February 2011.
2. United States Department of Justice; Drug Enforcement Agency (DEA): DEA: Drugs of Concern: Buprenorphine. 2011. Available at http.//www.deadiversion. usdoj.gov/drugs-concern/buprenorphine.pdf. Accessed May 1, 2011.
3. Centers for Disease Control and Prevention: Unintentional Drug Poisoning in the United States. Atlanta, GA: Centers for Disease Control, 2010: 1-4.
4. Warner-Smith M, Darke S, Lynskey M, et al.: Heroin overdose: Causes and consequences. Addiction. 2001; 96(8): 1113-1125. (Pubitemid 32738391)
5. Beletsky L, Burris S, Kral A: Closing Death's Door: Action Steps to Facilitate Emergency Opioid Drug Overdose Reversal in the United States (Conference Report). 2009. Philadelphia, PA: The Center for Law, Politics, and Policy, Temple University Beasley School of Law, 2009: 39.
6. Green TC, Heimer R, Grau LE: Distinguishing signs of opioid overdose and indication for naloxone: An evaluation of six overdose training and naloxone distribution programs in the United States. Addiction. 2008; 103(6): 979-989. (Pubitemid 351703471)
7. Kerr D, Kelly A-M, Dietze P, et al.: Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose. Addiction. 2009; 104(12): 2067-2074.
8. Doe-Simkins M, Walley A, Epstein A, et al.: Saved by the nose: By stander-administered intranasal naloxone hydrochloride for opioid overdose. Am J Public Health. 2009; 99(5): 788-791.
9. Maxwell S, Bigg D, Stanczykiewicz K, et al.: Prescribing naloxone toactively injecting heroin users: A program to reduce heroin overdose deaths. J Addict Dis. 2006; 25(3): 89-96. (Pubitemid 44352907)
10. Piper TM, Stancliff S, Rudenstine S, et al.: Evaluation of analoxone distribution and administration program in New York city. Subst Use Misuse. 2008; 43(7): 858-870. (Pubitemid 351892446)
11. Seal K, Downing M, Kral A, et al.: Attitudes about prescribing take-home naloxone to injection drug users for the management of heroin overdose: A survey of street-recruited injectors in the San Francisco Kay Area. J Urban Health. 2003; 80(2): 291-301. (Pubitemid 37486665)
12. Welsh C, Sherman SG, Tobin KE: A case of heroin overdose reversed by sublingually administered buprenorphine/naloxone (Suboxone). Addiction. 2008; 103(7): 1226-1228. (Pubitemid 351832254)
13. Boyd J, Randell T, Luurila H, et al.: Serious overdoses involving buprenorphine in Helsinki. Acta Anaesthesiol Scand. 2003; 47(8): 1031-1033. (Pubitemid 37013780)
14. Mendelson J, Jones RT: Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: Why the 4:1 ratio for treatment? Drug Alcohol Depend. 2003; 70(2 Suppl): S29-S37. (Pubitemid 36556058)
15. Bickel WK, Stitzer ML, Bigelow GE, et al.: Buprenorphine: Dose-related blockade of opioid challenge effects in opioid dependent humans. J Pharmacol Exp Ther. 1988; 247(1): 47-53.
16. United States Substance Abuse and Mental Health Services Administration: Center for Substance Abuse Treatment. Buprenorphine. Rockville, MD: US Federal Government, 2010. Available at http://buprenorphine.samsha.gov. Accessed October, 2010.
17. United States Substance Abuse and Mental Health Services Administration. Treatment Improvement Protocol 40 (TIP 40): Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Rockville, MD: US Federal Government, 2004: 169.
18. United States Department of Justice, Drug Enforcement Agency (DEA): Buprenorphine (Trade Names: Buprenex, Suboxone, Subutex). Springfield, VA: US Federal Government, 2011. Available at http://www.deadiversion.usdoj.gov/drugs- concern/buprenorphine.pdf. Accessed May 1, 2011.
19. Bazazi AR, Yokell M, Fu J, et al.: Illicit use of buprenorphine/naloxone among injecting and non-injecting opioid users. J Addict Med. 2011; 5(3): 175-180.
20. Monte A, Mandell T, Wilford B, et al.: Diversion of buprenorphine/ naloxone coformulated tablets in a region with high prescribing prevalence. J Addict Dis. 2009; 28(3): 226-231.
21. Nielsen S, Lintzeris N: The sublingual use of buprenorphine-naloxone for reversing heroin overdose: A high-risk strategy that should not be recommended. Addiction. 2008; 103(12): 2066-2067.
22. Raffa RB, Pergolizzi JV Jr: Opioid formulations designed to resist/deter abuse. Drugs. 2010; 70(13): 1657-1675.
23. United States Food and Drug Administration: FDA Approves New Formulation for OxyContin. FDA Press Release. April 5, 2010.
24. Okie S: A flood of opioids, a rising tide of deaths. N Engl J Med. 2010; 363(21): 1981-1985.
25. Rich J, McKenzie M, Green T: Response to"A flood of opioids, a rising tide of deaths". N Engl J Med. 2011; 364(7): 686.